Bridge City Capital LLC Raises Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Bridge City Capital LLC boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 54.8% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 160,739 shares of the company's stock after acquiring an additional 56,930 shares during the quarter. Harmony Biosciences accounts for about 1.6% of Bridge City Capital LLC's portfolio, making the stock its 17th biggest holding. Bridge City Capital LLC owned 0.28% of Harmony Biosciences worth $5,335,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of HRMY. Financial Management Professionals Inc. purchased a new position in Harmony Biosciences in the 1st quarter worth approximately $29,000. GF Fund Management CO. LTD. acquired a new stake in shares of Harmony Biosciences during the fourth quarter worth about $41,000. KBC Group NV raised its position in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after purchasing an additional 819 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after acquiring an additional 519 shares in the last quarter. Finally, Virtus Investment Advisers Inc. purchased a new position in Harmony Biosciences in the fourth quarter valued at $124,000. Hedge funds and other institutional investors own 86.23% of the company's stock.

Harmony Biosciences Trading Down 5.2%

HRMY stock traded down $1.81 on Thursday, hitting $33.33. 1,095,526 shares of the company were exchanged, compared to its average volume of 619,696. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 15.80, a price-to-earnings-growth ratio of 0.47 and a beta of 0.87. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The business's fifty day moving average is $32.14 and its two-hundred day moving average is $34.09.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.19. The business had revenue of $184.73 million for the quarter, compared to analyst estimates of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business's quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the company posted $0.67 EPS. As a group, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on HRMY shares. Needham & Company LLC restated a "buy" rating and set a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. UBS Group dropped their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a report on Monday, April 28th. Oppenheimer initiated coverage on shares of Harmony Biosciences in a research note on Monday, June 2nd. They issued an "outperform" rating and a $61.00 price objective on the stock. Cantor Fitzgerald raised Harmony Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, Mizuho lifted their price objective on Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $53.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.